69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
2 citations
,
December 2004 in “PubMed”
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly”
98 citations
,
April 1997 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively blocks rat enzymes, but with varying methods and strength.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib significantly improves hair regrowth in severe alopecia areata.
July 2025 in “American Journal of Clinical Dermatology” Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
February 2026 in “NeuroSci” Finasteride and dutasteride may cause depression and anxiety, especially in younger men.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
20 citations
,
January 2000 in “Dermatologic Clinics” New psoriasis treatments are effective but come with side effects and risks.
1 citations
,
August 2022 in “JAAD case reports” Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
7 citations
,
October 2019 in “Annals of palliative medicine” New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
September 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” AR-27 E-Chol siRNA can effectively promote hair regrowth for androgenetic alopecia.
1 citations
,
July 2026 in “Dermatology and Therapy” JAK inhibitors are generally safe for alopecia areata and atopic dermatitis, with mostly mild side effects.
9 citations
,
May 2014 in “Clinical Cosmetic and Investigational Dermatology” Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
March 2003 in “Oncology Times” Further research is needed to develop effective cancer prevention strategies.
September 2025 in “Blood Advances” Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
June 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” AQB reduces harmful skin changes in systemic sclerosis.